Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term finerenone extension study in children and young adults with chronic kidney disease and proteinuria
NL-OMON59300Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of finerenone in chronic kidney disease (CKD) and proteinuria, sponsored by Bayer. Primary endpoints: Number of participants with treatment-emergent adverse events, Change in serum potassium from baseline to Day 540±7 and 1 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)proteinuria
Beyond the preview
Go deeper on NL-OMON59300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59300.